Bristol Myers’ Lung Drug Works. Now Explain the Dose Split.
Admilparant hit Phase 3 FVC at 60mg, but the 120mg miss complicates the FDA story.
Admilparant hit Phase 3 FVC at 60mg, but the 120mg miss complicates the FDA story.
The Cypress fund’s Q3 collapse shows what went wrong in crowded AI infrastructure bets.
After Firmus’s failed IPO, private capital is abandoning AI data centres for physical AI. Here are the listed names in the path of that shift.
Meta’s ByteDance ad ban raises a reallocation question, and one challenger looks better positioned than the other.
A $22 billion deal fell apart, and the Oct. 22 deadline is real
The IIJA fiscal-year rollover is accelerating a shift toward subscription-style water delivery.
China’s October fuel exports look modest, but three other risks deserve equal attention ahead of Valero’s Oct. 22 earnings report.
A new Bank of England survey shows UK card defaults rising again
Michigan’s Oct. preliminary sentiment hits at 10:00am ET. With year-ahead inflation expectations at 4.6% and gas at $4.36 a gallon, the inflation figure matters more than the index.
Fed minutes signaled another hike could come this year. Now small caps, banks, and utilities face a reckoning at multi-decade yield highs.